G1 Therapeutics Inc (GTHX)
2.45
-0.02
(-0.81%)
USD |
NASDAQ |
Jul 02, 16:00
2.45
0.00 (0.00%)
After-Hours: 20:00
G1 Therapeutics SG&A Expense (Annual): 71.13M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 71.13M |
| December 31, 2022 | 100.42M |
| December 31, 2021 | 95.69M |
| December 31, 2020 | 68.49M |
| December 31, 2019 | 40.04M |
| Date | Value |
|---|---|
| December 31, 2018 | 18.60M |
| December 31, 2017 | 7.087M |
| December 31, 2016 | 5.23M |
| December 31, 2015 | 3.216M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
40.04M
Minimum
2019
100.42M
Maximum
2022
75.15M
Average
71.13M
Median
2023
SG&A Expense (Annual) Benchmarks
| Alimera Sciences Inc | 46.48M |
| ResMed Inc | 874.00M |
| NovaBay Pharmaceuticals Inc | 12.83M |
| Palatin Technologies Inc | 15.29M |
| iBio Inc | 19.02M |